Dynavax Technologies Corporation Aktie News

Today, I am highlighting three biotech stocks I like in the current market that are trading at under $10.00 a share. The options on these stocks are also lucrative and liquid, making them well-suited for consistent covered call trades. Covered call strategies offer downside protection in the underperforming, high-beta biotech sector, supporting a rinse, wash, and repeat approach.

EMERYVILLE, Calif. , Aug. 27, 2025 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines, today announced that the Company will participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd at 4:30 p.m.

Dynavax Technologies said on Thursday its experimental shingles vaccine generated a similar immune response as GSK's blockbuster shot Shingrix, while showing a better safety profile, in early-to-mid-stage study.

At all doses and formulations evaluated in Part 1 of the trial, Z-1018 was well-tolerated and demonstrated a favorable tolerability profile, including lower solicited local and systemic post-injection reactions, versus Shingrix Z-1018 demonstrated robust immune responses in all dose arms, including a 100% humoral vaccine response rate at the dose selected for advancement, with comparable immuno...

Dynavax delivered strong Q2 results, beating expectations and narrowing guidance, and Heplisav-B continued to sport market share gains and profitability. Heplisav-B is best-in-class in its niche, and management is projecting significant sales and market share growth through 2030. Dynavax boasts a robust balance sheet, recently completed a $200M buyback, and is well-regarded by analysts, support...

Dynavax Technologies Corporation (NASDAQ:DVAX ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Donn Casale - Senior VP & Chief Commercial Officer Kelly MacDonald - Senior VP & CFO Paul Cox - VP of Investor Relations & Corporate Communications Robert Janssen - Chief Medical Officer and Senior VP of Clinical Development, Medical & Regulatory Affairs Ryan Spencer -...

Dynavax (DVAX) Q2 Revenue Jumps 29%

Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growth Refines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 million Top-line results in Part 1 of Phase 1/2 shingles vaccine trial expected in August 2025 Completed dosing in Part 1 of Phase 1/2 trial of pandemic influenza adjuvant program C...